| By Big Radio News Staff |
Beloit’s NorthStar Medical Radioisotopes aims to become a star in cancer treatment drugs.
NorthStar CEO Frank Scholz says the nuclear medicine startup will fire up commercial production of cancer diagnostic and treatment drugs later this year in two new facilities on its Beloit campus that the company is calling Building 4 and Building 5.
This coming week, NorthStar will host a ceremonial opening of Building 5, a 55,000-square-foot facility where NorthStar will make drugs derived from multiple radioactive rare-earth materials, such as radioactive actinium-225. Building 4 will begin commercial production of actinium isotopes later this year.
The drugs are intended for distribution to radiopharmacies and cancer therapy centers throughout the U.S.
NorthStar’s upcoming moves are being watched closely by the medical and pharmaceutical community. NorthStar will produce radioactive drugs that target specific cancers, including prostate cancer.
